Progression of cataracts following photodynamic therapy combined with intravitreous triamcinolone injection in cases of age-related macular degeneration.
Abstract
BACKGROUND
To present long-term data on the progression of cataracts following photodynamic therapy (PDT) combined with 4 mg intravitreal
triamcinolone acetonide (IVTA) for age-related macular degeneration (AMD).
METHODS
Fifty-seven phakic eyes of 56 patients underwent the treatment between October 2004 and November 2006. The follow-up period
ranged from 12 to 38 months with 3 months interval of observation and repeated treatment at recurrence.
RESULTS
Cataract progression was noted in 40 eyes 5-21 months after treatment, consisting of 4 eyes between 3 and < 6 months after
treatment, 22 eyes between 6 and < 12 months, 8 eyes between 12 and < 18 months, and 6 eyes between 18 and < 24 months. The
percentage of the eyes with cataract progression began to decrease 5 months after treatment and, occurred most frequently
during the period from 6 months to 12 months after treatment. There was no significant difference in age, follow-up period,
or the frequency of the treatment between the cataract progression group and the non progression group. Twenty four eyes underwent
surgery 10-31 months after treatment, showing significant improvement in visual acuity.
CONCLUSIONS
This study showed high incidence of cataract during a long-term follow-up after PDT combined with IVTA and significant reduction
of visual acuity due to cataract.
Authors
Iwami H, Kohno T, Yamamoto M, Kaida M, Miki N, Ataka S, Shiraki K
Institution
Department of Ophthalmology and Visual Sciences, Osaka City University, Graduate School of Medicine, Japan. iwami-oss@umin.ac.jp
Source
Osaka city medical journal 57:2 2011 Dec pg 49-57MeSH
AgedAged, 80 and over
Cataract
Cataract Extraction
Disease Progression
Female
Glucocorticoids
Humans
Intravitreal Injections
Macular Degeneration
Male
Middle Aged
Photochemotherapy
Retrospective Studies
Time Factors
Treatment Outcome
Triamcinolone
Visual Acuity
Pub Type(s)
Journal ArticleLanguage
eng
PubMed ID
22443078
Log In

